Q1 2025 Tempus AI Inc Earnings Call Transcript
Key Points
- Quarterly revenue increased by 75.4% year-over-year to $255.7 million, showcasing strong financial performance.
- Genomics revenue saw an impressive 89% year-over-year growth, contributing significantly to overall revenue.
- The company announced a 3-year $200 million data and modeling license agreement with AstraZeneca and Pathos, enhancing its strategic partnerships.
- Adjusted EBITDA improved significantly, reducing the loss from $43.9 million in Q1 2024 to $16.2 million in Q1 2025.
- Tempus AI Inc (TEM) raised its full-year 2025 revenue guidance to $1.25 billion, indicating confidence in continued growth.
- Despite revenue growth, the company reported a negative adjusted EBITDA of $16.2 million, indicating ongoing financial challenges.
- The cost of compute for the new data model is significant, although partially covered by partners.
- The MRD (Minimal Residual Disease) tests are not yet reimbursed by MolDx, leading to metered volumes and potential revenue limitations.
- There is a risk of over-reliance on large pharma contracts, which could be impacted by broader economic conditions.
- The hereditary testing business, while performing well, is still subject to market perceptions of commoditization and long-term growth uncertainty.
Good day, everyone, and thank you for standing by. My name is RG, and I will be your conference operator today. At this time, I would like to welcome everyone to the first quarter 2025 financial results conference call. (Operator Instructions) Thank you.
I would now like to turn the call over to Liz Krutoholow, VP for Investor Relations. Please go ahead.
Thank you. Good afternoon and welcome to Tempus' First Quarter 2025 Conference Call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press release and overview of the quarter and our latest presentation are available on our IR website. Joining me today from Tempus are Eric Lefkofsky, Founder and CEO of Tempus; and Jim Rogers, CFO.
Before we begin, I would like to remind you that during this call, management may make forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to our 10-K and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
